Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0242379 (lung cancer)
 71,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The activity of adenosine deaminase (EC 3.5.4.4.) was significantly lower in lymphocytes from patients with lung cancer than in those from healthy subjects, whereas the activity of purine nucleoside phosphorylase (EC 2.4.2.1.) was significantly higher in lymphocytes from the patients than in those from normal controls. When the one activity was plotted against the other, the plots for patients with lung cancer were all outside the frame formed by the lower and higher limits of the standard deviation of the mean of normal activities of the two enzymes. The ratio of adenosine deaminase activity to purine nucleoside phosphorylase activity was lower in patients with lung cancer than in controls. The possible effect of this ratio on the function of lymphocytes was briefly discussed. These enzyme activities were suggested to be useful measures of the immune responsiveness of patients with lung cancer.
 ...
PMID:Adenosine deaminase and purine nucleoside phosphorylase activities in lymphocytes from patients with lung cancer. 10 12

A study of the feasibility of using specially trained radiologic technologists to screen chest radiographs was undertaken as part of an early lung cancer detection program. In their initial examination, 8,000 men had posteroanterior and lateral chest films which were prepared and evaluated by two specially trained technologists prior to interpretation by a radiologist. The technologists' accuracy in screening was subsequently assessed by comparison with the radiologist's interpretation and with clinical follow-up information. There were differences in the level of suspicion of the two technologists, but both were effective in selecting a subset of the screened population that contained the men with radiologically identifiable lung cancer.
 ...
PMID:Accuracy of chest film screening by technologists in the New York early lung cancer detection program. 10 46

In the present work the results of a radiotherapy protocol for the treatment of inoperable lung cancer are examined. The study was carried out on two groups of patients treated successively; the first of 140 patients by means of cobalt therapy at the normal rate, up to a dose of 4,500 to 5,000 rads in 5 weeks; the second of 221 cases by means of concentrated radiotherapy in two series of 2,000 rads in five sessions, separated by 3 weeks of rest. The results show a more rapid regression of the symptomatology in the second group of patients and a clear superiority in respect to the survival rate. The patients treated at the normal rate showed after 6 months a survival rate of 40 percent as against 60.5 percent in the second group. This difference became more evident when comparing the histologic types: 9 and 57 percent respectively for anaplastic carcinomas. The survival rate after 1 year shows a difference between the two groups which is statistically significant (16 and 21 percent respectively) (p less than 0.05). In no case did we find complications of the type of esophagitis, pericarditis or transverse myelitis. The treatment in two sessions was better tolerated both from the physical and the psychic point of view by all the patients because of the 3 weeks of rest. The superiority in regard to survival, the rapid disappearance of the symptomatology, as well as the reduction in the therapy time, justify the use of concentrated radiotherapy in the treatment of this type of tumors even in the more advanced stages of the disease.
 ...
PMID:[Treatment of inoperable lung carcinoma by means of concentrated radiotherapy: results from 361 cases (author's transl)]. 10 77

A human lung tumor-associated fetal antigen (LTFA) has been partially isolated and characterized. The antigen that differs in several immunochemical parameters from previously described lung cancer antigens was shared by fetal lung and liver tissue. The neoantigen migrated in immunoelectrophoresis as an alpha2-beta globulin, had an average molecular size of 7S, and was soluble in 50% saturated ammonium sulfate. Whereas LTFA was insensitive to both DNase and RNase treatment, its antigenicity was completely abolished by pronase. The biologic significance of this antigen and its possible clinical use were discussed.
 ...
PMID:Partial characterization of a fetal lung antigen associated with human bronchogenic carcinoma. 10 44

As a preliminary step in the identification and isolation of antibodies to human cancers, we have developed a sensitive and convenient assay for antibody binding to cellular antigens. The basis for the method is antibody binding to glutaraldehyde-fixed cells (AbGfC) and quantitation with radioiodinated staphylococcal protein A (SpA). Glutaraldehyde fixation of intact cells, which does not appear to effect the ability to form antigen-antibody complexes, provides a convenient and standard supply of target cells which may be stored at 4 degrees C and used in the assay over a period of several months. The amount of antibody specifically bound to the cells is quantitated by the addition of 125I-labeled SpA. The sensitivity of the method was compared with two complement-dependent cytotoxicity methods (trypan blue exclusion and 51Cr release assays) and tested with two antisera to human lung cancer and one antiserum to a membrane antigen of a murine lymphoma. These comparisons indicated much greater sensitivity when compared with the trypan blue exclusion assay and equivalent sensitivity with greater dose response characteristics when compared with the 51Cr release assay.
 ...
PMID:Sensitive and convenient quantitation of antibody binding to cellular antigens using glutaraldehyde preserved cells. 11 Aug 84

Since the introduction of bone scans in 1951, there have been many studies comparing biologic and physical characteristics of new bone-imaging agents and the results of scintigraphy and radiology in large numbers of patients. Relatively speaking, there have been fewer studies detailing the health benefits and financial cost associated with the use of skeletal scintigraphy. This review concerns these aspects in patients with malignancies of various sites and stages. About 2% of patients with stage I or II breast cancer have bone metastases at the time they first present, whereas nearly 28% of patients with stage III disease have bone metastases. A large percentage of patients with initially negative scans develop bone metastases during the first 3--4 yr; many of them develop them within the first 12--18 mo after initial diagnosis. For patients with lung cancer, the use of bone scans in staging their disease is somewhat controversial. Several studies indicate that the yield of positive bone scans may range from as low as 2% to as high as 35%. Data on the use of bone scans in staging prostatic cancer initially are similar to those in patients with breast cancer, that is, yields of 7% in patients with stage I or II disease and a yield of about 20% with stage III disease. Children with osteosarcoma or Ewing's sarcoma rarely have bone disease distant from the site of their primary bone lesion at presentation. However, a large percentage of them (30%--40% or so) develop bone metastases during the follow-up period. As in the case with patients with breast cancer, about half of these bone metastases are evident by 12--18 mo.
 ...
PMID:Rationale for the use of bone scans in selected metastatic and primary bone tumors. 11 84

104 patients with various cancer, excluding malignant lymphoma and leukemia, underwent bone marrow biopsy using a Jamshidi needle, regular type. In 100 patients an adequate pice of bone marrow was obtained. In 24 patients metastases were detected in the bone marrow. Metastases were found in 10 of 38 (26.3%) patients with breast cancer, in 5 of 17 (29.4%) patients with lung cancer, in 5 of 10 (50%) patients with cancer of the prostate, in 1 patient with rhabdomyosarcoma, 1 with chordoma and in 2 of 14 patients who underwent biopsy in search of unknown cancer. 71% of the patients with positive findings in the bone marrow had clinical signs of bone involvement, 80% had positive X-ray film and 78.9% had positive skeletal isotope survey. Hemogram, serum alkaline phosphatase, serum calcium level and sedimentation rate were of no value in predicting whether the marrow was involved or not. No complications were documented following biopsy. The use of the Jamshidi bone marrow biopsy needle for staging and early detection of metastases in a select group cancer patients is suggested.
 ...
PMID:Bone marrow biopsy in patients with malignant neoplasms other than lymphomas or leukemia. 11 9

The inhibitory effect of the thoracic duct lymph of a patient with lung cancer on the "one-way" mixed lymphocyte reaction without cytoxicity is unequivocally demonstrated. The effect seems to be dose related. A moderate inhibition of mixed lymphocyte reaction is still observed, even if the responding cells are preincubated in the thoracic duct lymph for 1 hr only prior to the addition of stimulating cells. The inhibitory effect of thoracic duct lymph on the mixed lymphocyte reaction is no longer evident when the material is added 1-4 days after the beginning of culture. These observations suggest that the mechanism of the inhibitory effect of thoracic duct lymph may be a simple attachment of inhibitory factors to the receptor sites on the responding lymphocytes, causing interference in cell to cell interaction. The inhibitory effect of thoracic duct lymph collected 1 week after the thoracic duct drainage on mixed lymphocyte reaction is significantly lower than that of thoracic duct lymph collected at the beginning of the procedure. This indicates that the blocking effect of thoracic duct lymph can be easily removed by this technique; which is technically feasible in man. The interrelationship of the tumor-specific blocking factor, thoracic duct drainage, and tumor growth pattern are discussed with respect to the potential usefulness of this procedure as adjuvant immunotherapy in the management of patients with neoplastic diseases.
 ...
PMID:Inhibition of mixed lymphocyte reaction by thoracic duct lymph: removal of inhibitory effect by thoracic duct drainage in lung cancer. 13 73

The authors report the data on lung cancer metastases in abdominal and retroperitoneal space organs in 174 patients died due to postoperative complications during 2 months following resection of the lung. Distant metastases were recognized in 32 cases (18.3%). 29 of 49 metastases (58%) were detected in abdominal organs. In stages I-II remote metastases were found in 2 of 32 cases, in stage III--in 29 of 142 cases, i.e. 35 times as frequently. Laparoscopy and laparotomy, performed if indicated, are conclusive surgical methods of establishing the precise diagnosis of the tumor spread, and these allow the elaboration of a rational plan of treatment in lung cancer patients.
 ...
PMID:[Detection of late lung cancer metastases]. 13 11

Eighty one patients (59 females, 22 males) with advanced solid tumors were treated with Adriamycin in doses of 40 mg/m2 body surgace daily, in two days cycles, with resting periods of 3 weeks. Overall response rate was 46% (37/81). In breast cancer response rate was 56% (13/23) and in ovarian cancer 48% (13/27). In various other tumors remission was observed in soft tissue sarcomas (3/8), thyroid cancer (1/7), osteogenic sarcoma (1/4), oesophageal cancer (2/4), lung cancer (2/4), bladder cancer (1/2) and hepatoma (1/2). In breast cancer patients, 2-7 month remission duration was observed (M equal to 4.5 month) and in ovarian cancer 1.5-5 month (M equal to 3.2 month). Adriamycin was also applied intrapleurally in 31 patients with malignant pleural effusions with a low response rate (26%). This modified schedule of Adriamycin administration showed a high antitumor activity in breast and ovarian cancer and in soft tissue sarcomas. Squamous cell carcinoma of the esophagus was also sensitive to Adriamycin therapy. The very low rate of myelosuppression and oral ulceration showed the decreased toxicity of this Adriamycin administration schedule.
 ...
PMID:Modified administration schedule of adriamycin in solid tumors. 14 May 42


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>